E
Elutia Inc. (ELUT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
$0.82
+0.00 (+0.35%)
Market Cap: $36.41M
Last updated: Nov 17, 2026 at 10:51 AM ET
Elutia Inc. (ELUT) P/E Ratio & Valuation History
Elutia (ELUT) trades at 0.8x trailing earnings and 10.9x sales. Its P/S of 10.9x is above its 5-year median of 3.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | 0.8x |
| Forward P/E | N/A |
| Price to sales | 10.9x |
| Price to book | 2.4x |
| PEG | N/A |
| FCF yield | -139.0% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 10.9x | 3.0x | N/A |
Valuation History
Over the 5 of the 6 year ends shown that have a P/S, its P/S ranged from 1.4x in 2021 to 7.4x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $0.69 | 0.7x | 7.4x | 1.2x |
| 2024 | $3.74 | N/A | 6.4x | N/A |
| 2023 | $2.16 | N/A | 1.5x | N/A |
| 2022 | $4.25 | N/A | 2.4x | N/A |
| 2021 | $6.30 | N/A | 1.4x | 8.2x |
| 2020 | $13.63 | N/A | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ELUT
Is ELUT stock overvalued?
GNG's valuation label for ELUT is Overvalued.
What is ELUT's price to sales ratio?
Elutia has a price to sales ratio of 10.9x.
ELUT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors